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Background: Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the
community. Acute exacerbations of COPD (AE-COPD) often result in administration of antibiotics although more
than half of exacerbations are associated with detection of respiratory viruses and potentially pathogenic bacteria
can only be detected in 20-30% of cases. There is a paucity of placebo-controlled clinical trials and up to today no
single study has been powered sufficiently to prove the efficacy of antibiotic treatment in AE-COPD. Most studies
so far did not include current standards of care comprising administration of systemic corticosteroids.
Methods/Design: A total of 980 patients with moderate acute exacerbations will be included in 22 German centers
(hospitals and private practices). Patients will receive a standardized treatment for exacerbation including systemic
corticosteroids, inhaled bronchodilators and supplementary oxygen if needed and will be randomized to additional
treatment with placebo or antibiotic (oral sultamicillin) for five days.
The primary endpoint is clinical failure defined by need for additional antibiotic treatment until day 30. Secondary
endpoints will assure that management of AE-COPD without antibiotics does not result either in increased occurrence
of relapse, new exacerbations, prolonged recovery, or unwanted long-term consequences.
Discussion: ABACOPD will be the first sufficiently powered double-blind placebo-controlled study in the field to
systematically assess the question whether antibiotics, known to increase antibiotic resistance, are really needed in a
well-defined patient cohort receiving state-of-the art treatment in all other aspects.
Trial registration number: ClinicalTrials.gov: NCT01892488.Background
Antibiotic resistance is increasing in hospitals as well
as in the community. It has been shown that antibiotic
prescriptions without a clear indication contribute sig-
nificantly to this increase [1]. Acute exacerbations of
COPD (AE-COPD) represent a frequent clinical situation
in which administration of antibiotics is considered. In
2010 nearly 700.000 hospital discharges for COPD in the
U.S. [2] have been registered. A retrospective cohort study
identified that antibiotics were prescribed in 85% of 69* Correspondence: g.rohde@mumc.nl
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unless otherwise stated.820 patients admitted for acute exacerbations of COPD to
360 hospitals throughout the United States [3]. This is im-
pressive as evidence of efficacy of antibiotic treatment of
AE-COPD is scarce. It is estimated that about 70% of
exacerbations are infectious in origin [4]. However, only
20-30% are associated with detection of bacteria by spu-
tum culture [4]. Importantly, detection of pathogens by
culture is not per se a proof of infection. Particularly in
COPD patients growth of bacteria in sputum cultures can
also result from colonization of the airways [5]. Up to now
colonization is not considered as a clear indication for
antibiotic treatment. In addition, others and we have
shown that respiratory viruses are detected in more than
50% of exacerbations and also have to be considered as
major infectious triggers [6,7]. In viral infections antibioticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Rohde et al. BMC Pulmonary Medicine 2015, 15:5 Page 2 of 7
http://www.biomedcentral.com/1471-2466/15/5therapy is not expected to be effective [8]. Moreover anti-
biotic treatment is associated with increased morbidity,
mainly reflected by gastro-intestinal complications such as
diarrhoea, often caused by C. difficile [9].
A recent Cochrane review assessed the effects of anti-
biotics in the management of acute COPD exacerbations
on treatment failure as observed between seven days and
one month after treatment initiation (primary outcome)
and on other patient-important outcomes (mortality,
adverse events, length of hospital stay) [10]. In this most
recent systematic review using GRADE methodology
[11] 16 trials with 2068 participants were included. Outpa-
tients were considered to have mild to moderate exacerba-
tions. Only the most recent trial showed a benefit of
antibiotic treatment and drove the results towards benefi-
cial effects of antibiotics [12]. When the meta-analysis was
restricted to currently available drugs however, there was
no significant benefit but just a trend in favour of antibi-
otics (RR 0.80; 95% CI 0.63 to 1.01; I2 = 33%) [10]. How-
ever, evidence of high quality showed that antibiotics
significantly reduced the risk of treatment failure in inpa-
tients with severe exacerbations (ICU not included) (RR
0.77; 95% CI 0.65 to 0.91; I2 = 47%) regardless of whether
restricted to current drugs or not. There still is only one
trial with 93 patients admitted to the ICU, which was also
analysed in this review [13]. This trial showed a large and
statistically significant effect on treatment failure (RR 0.19;
95% CI 0.08 to 0.45; high-quality evidence) [10]. In studies
addressing mortality evidence of low-quality from four tri-
als in inpatients showed virtuality no effect of antibiotics
on mortality (Peto OR 1.02; 95% CI 0.37 to 2.79) [10].
Length of hospital stay (in days) was similar in the antibi-
otics and placebo groups except for the ICU study. The
overall incidence of adverse events was higher in the anti-
biotics groups (Peto OR 1.53; 95% CI 1.03 to 2.27). Pa-
tients treated with antibiotics experienced more diarrhoea
based on three trials (Peto OR 2.62; 95% CI 1.11 to 6.17;
high-quality evidence) [10]. The authors concluded on the
basis of these findings that for outpatients and inpatients
the results were inconsistent. The risk for treatment fail-
ure was significantly reduced in both inpatients and out-
patients when all trials (1957 to 2012) were included but
not when the analysis for outpatients was restricted to
currently used antibiotics. Also, antibiotics had no statisti-
cally significant effect on mortality and length of hospital
stay in inpatients and almost no data on patient-reported
outcomes exist [10]. The appraisal of the results of this
systematic review is largely impaired by the fact that there
was no pre-defined standard treatment of AE-COPD in-
cluding corticosteroids, even not in the most recent trials.
Therefore it is impossible to judge the benefit of antibiotic
treatment in addition to standard treatment of AE-COPD.
It is remarkable that on this brittle basis, antibiotic
treatment for AE-COPD is recommended for patientswith severe exacerbations or severe underlying COPD
[8]. Moreover, most AE-COPD are mild to moderate
and not severe and it seems difficult to extrapolate the
findings from one positive ICU study to the less severe
situations.
In conclusion there still is no clear recommendation
for antibiotic treatment for these patients. These facts
underline that a randomized, placebo-controlled trial on
antibiotics for mild to moderate AE-COPD is warranted
[8]. In light of the fact that respiratory viruses are de-
tected in 50% of exacerbations a major task is the reduc-
tion of unnecessary antibiotic treatment in patients with
mild to moderate COPD exacerbations to stop the
threatening increase in AB resistance [8]. It has been
convincingly shown that prudent reduction of antibiotic
use results in a decrease of bacterial resistance without
an increase in complications [14]. Taken this important
aspect into account it seems that the risk-benefit ratio of
antibiotic treatment for mild to moderate AE-COPD is
negative and should therefore be discouraged. The most
recent study [15] showed that it is safe to treat AE-COPD
patients with all grades of disease severity (GOLD 1 to 4)
with placebo if standardized treatment is provided. All
studies performed so far were designed to prove efficacy
of antibiotics in AE-COPD [8].
Against this background we have designed a random-
ized double blind placebo-controlled study to demonstrate
that antibiotics are not needed in moderate acute exacer-
bations of COPD – The ABACOPD Study. ABACOPD is
the first study designed to show non-inferiority of placebo
in AE-COPD proving that antibiotics are not needed. This
might have important impact to individual patients as well
as to society. It has been shown in several trials that
adverse events are more frequent in patients treated with
antibiotics than in patients on placebo [16]. Hence the in-
dividual patient might benefit from reduced adverse
events associated with antibiotic treatment if antibiotics
are no longer prescribed for this indication. In addition
the individual patient might also benefit from decreased
selection of antibiotic resistant strains by reduction of
antibiotic consumption. Society will clearly benefit if un-
necessary antibiotic prescriptions will be reduced. This
has been convincingly shown in other settings [14]. At last
there is a potential economic impact. Antibiotic therapy
can be costly and it has been shown that reduction in anti-
biotic use significantly reduces costs [17].
Methods
Objective
The ultimate goal is to reduce unnecessary antibiotic
prescriptions, which drive the development of antibiotic
resistance in the community. The primary objective of
ABACOPD is to demonstrate in a sufficiently sized
clinical study that there is no relevant increase in the
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bations of COPD (AE-COPD) treated with placebo in-
stead of antibiotic treatment both on top of standard of
care. A patient is classified as treatment failure if add-
itional antibiotic therapy is required during the initial
treatment period or until the test of cure visit (TOC at
day 30, primary endpoint). Secondary objectives are to
demonstrate that patients on placebo do not experience
more frequent relapse or show prolonged symptoms. A
patient is classified as relapse if new antibiotic therapy for
AE-COPD is required within the first six months after
TOC. Clinical cure rates at end of treatment (EOT) and
TOC will inform about duration of symptoms and speed
of recovery.
Intervention
Each patient will receive inhaled short-acting bronchodila-
tors, systemic corticosteroids (prednisolone 40 mg/d p.o.
for 7–10 days) and oxygen in case of hypoxemia in a stan-
dardized fashion. The pre-existing COPD medication will
be continued as indicated. All patients in the study will
receive, per randomized allocation, treatment with either
antibiotic therapy or placebo. Those randomized to
antibiotic therapy will receive 750 mg sultamicillin
(two 375 mg capsules) twice a day (BID) for 5 days. An
Aminopenicillin plus betalactamase inhibitor is the rec-
ommended antibiotic treatment for moderate AE-COPD in
Germany [18]. The treatment duration of 5 days is chosen
because the latest interventional trial in lower respiratory
tract infections showed for patients with AE-COPD that
5 days of treatment is safe and effective and that even
shorter duration can be used if procalcitonin guidance is
employed [19]. Those patients randomized to the placebo
will receive two placebo capsules twice a day (BID) for
5 days. The duration of treatment with study medications
will be 5 days.
Key inclusion criteria
Patients will be enrolled into the study when diagnosed
with moderate acute exacerbation of COPD according to
the definition of the Global initiative for chronic Obstruct-
ive Lung Disease (GOLD) without respiratory failure or
need for intermediate or intensive care if they fulfill the
following criteria:
– Male and non-pregnant female adults, older than
40 years of age, diagnosed with COPD stages I-IV as
defined by GOLD
– Doctor’s diagnosis of acute (onset < 7 days)
moderate exacerbation of COPD (definition see 3.2),
necessitating the administration of systemic
corticosteroids
– Procalcitonin level < 0.25 ng/mL (to rule out
community acquired pneumonia or lowerrespiratory tract infection with a clear indication for
antibiotic treatment)
– Smoking history of 10 Pack Years or more
Key exclusion criteria
– Severe exacerbation defined by need for ventilatory
support indicated by PaCO2 > 45 mmHg and/or
pH < 7.35, mental confusion, or unstable comorbiditiy
– Pneumonia (proven by chest x-ray performed in
suspected cases)
– Fever (>38.5°C)
– Known impaired hepatic or renal function
– Active or suspected tuberculosis infection of the
respiratory tract
– Acute exacerbation of asthma
– Suspected or known hypersensitivity to, or
suspected serious adverse reaction to Sultamicillin
– Immunosuppression or Immunosuppressive therapy
– Antibiotic use within 30 days prior to randomization
– An antibiotic is clearly indicated for treatment of a
known infection
– Known MRSA colonization or infection
– Patients with known bronchiectasis
Outcomes
Primary efficacy endpoint
A test of cure (TOC)-visit will be performed at day 30
after start of the treatment phase. A patient is classi-
fied as a treatment failure if additional antibiotic ther-
apy is required during treatment period or until the
TOC-visit. For each treatment arm a failure rate will
be computed.
Key secondary endpoint(s)
– Relapse rate at late follow-up (LFU-1) 6 months
after the start of treatment, and time to relapse;
exacerbation rate at late follow-up (LFU-2, one year
after start of treatment), and time to next exacerbation;
clinical cure rate at the EOT visit and clinical cure rate
at the TOC visit (both determined by patient-reported
outcome (diary cards). Spirometry will be assessed at
LFU-2 to assess long-term consequences.
Assessment of safety:
Key criteria for safety are
– Adverse events
– Serious adverse events
– Incidence of complications (Need for intensive care
unit treatment, need for ventilatory support)
– Vital status
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Efficacy/test accuracy
A patient is classified as a treatment failure if additional
antibiotic therapy is required during treatment period or
until the test of cure visit (TOC at day 30, primary
endpoint).
The primary analysis will be stratified for centre. A
two-sided 95%-confidence interval will be computed for
the difference in failure rates for placebo minus experi-
mental treatment group. The null-hypothesis of relevant
inferiority of the placebo treatment will be rejected in
favor of the alternative that antibiotic treatment is not
required in this patient population, if the upper bound
of the confidence interval does not exceed 10%, which is
standard for the comparison of antibiotic treatments. The
primary analysis will be conducted on the ITT-population
including all randomized patients that have taken experi-
mental drug or placebo at least once. A conservative rule
will count missing values in the placebo-group with treat-
ment failure, and as success in the active treatment group.
Sample size calculation
A limited number of studies have compared antibiotic
treatment to placebo in patients with AE-COPD. Jorgensen
et al. [20] found in 1992 a 63% success rate with placebo
as compared to 64% with Amoxicillin after 7 days of treat-
ment of uncomplicated exacerbations of chronic bron-
chitis. In contrast Anthonisen et al. [21] found in 1987 a
55% success rate with placebo and a 68% response rate
with antibiotic treatment for 10 days. Daniels et al. [15]
observed in 2010 a clinical success in the first study using
a standardized treatment including systemic corticoste-
roids in 61% of patients from the doxycycline group and
53% from the placebo group. In all these studies back-
ground standard of care has not been optimized and it is
assumed that this is the reason for observed differences in
small studies. It is thus assumed that the response rate in
the study population will be in the order of 65%. With a
one-sided type 1 error of 2.5% 479 patients per group have
to be recruited to reject the null-hypothesis of relevant
inferiority of placebo treatment with 90% power and a
non-inferiority margin of 10%. (Sample-size calculation
has been performed with nQuery-Advisor 7.0).
Safety
Adverse events and serious adverse events will be sum-
marized per treatment group and descriptively compared
between treatment-groups with a Chi-Square test.
Secondary endpoints:
Secondary analyses will investigate the relapse rate
(new antibiotic treatment needed for AE-COPD within
six months), time to relapse, the treatment effect with
respect to clinical cure rates and failure rates at end-
of-treatment (EOT)-visit and the TOC-visit in themodified ITT (mITT) population and the clinical eva-
luable (CE)-population. Exacerbation rates and time to
next exacerbation will be assessed within 1 year after
the index exacerbation.
Study populations
We have calculated that 1300 patients have to be
assessed for eligibility to have 980 patients to be allo-
cated to trial. Ultimately 960 patients will be analysed.
The total duration of the trial is calculated to be
36 months. Based on the feedback of the study centres
of our research network we have calculated that 22
German centers need to be involved to guarantee
adequate recruitment.
Consent statement
Written informed consent for participation in the study
will be obtained from all participants.
Ethics statement
The study has been approved by the ethics committee
(EC) of the Hannover Medical School (Nr. 6414 M) and
the ECs of all local clinical centers.
Discussion
The novel aspect of the proposed trial is to investigate
non-inferiority of placebo against adequate antibiotic
treatment in addition to well-defined standardized treat-
ment of moderate AE-COPD in order to show that anti-
biotics are not needed for this indication. The generally
accepted standard of care for patients with AE-COPD is
administration of inhaled short-acting bronchodilators,
systemic corticosteroids (prednisolone 40 mg/d for 7–10
days) and oxygen in case of hypoxemia. All patients in
this study will receive this treatment during exacerbation.
In the meantime a study has been published indicating
that even shorter duration of corticosteroid treatment
(5 days) is effective [22]. We consider this as important
new information to the field but do not think that this has
relevant implications for our study and the standard treat-
ment is the same for both study arms. The role of antibi-
otics is debated and in the recent trial from Daniels et al.
antibiotic treatment was not significantly more effective
than placebo. Clinical success was 53% in the placebo
group compared to 61% in the doxycycline group, p = 0.32
[15]. Llor et al. have very recently published a trial of
amoxicillin/clavulanate (AMX) 500/125 mg three times a
day compared to placebo three times a day for 8 days in
patients with mild to moderate COPD [12]. 158 patients
received AMX and 152 placebo. However, only 26 (16.5%)
and 27 (17.8%) received oral corticosteroids, which again
points to the problem of insufficient standard treatment
and the difficulty to validly assess the effects of antibiotic
treatment.
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question as they did not use standardized treatment for
AE-COPD including systemic corticosteroids. Therefore
it is justified that patients will be randomised to either
receive additional antibiotic treatment of or placebo if
standard treatment (see above) is provided.
The choice of antibiotic treatment in AE-COPD is also
a matter of debate. However, the most recent discussion
clearly indicated that patients are likely to derive greatest
benefit from early treatment with the most potent anti-
biotic therapy, such as amoxicillin/clavulanate and respira-
tory fluoroquinolones which have a broad spectrum of
activity against likely pathogens [23]. Sultamicillin belongs
to the first category and therefore we are confident that it
is a good choice for this study.
If the primary study outcome is met the community
will benefit from reduced consumption of antibiotics.
The study will include 960 patients and will be sufficiently
powered to precisely estimate a potential risk from waiv-
ing anti-biotic treatment and to definitively answer this
crucial clinical question.
A limited number of studies have compared antibiotic
treatment to placebo in patients with AE-COPD. Jorgensen
et al. [20] found in 1992 a 63% success rate with placebo
as compared to 64% with Amoxicillin after 7 days of treat-
ment of uncomplicated exacerbations of chronic bron-
chitis. In contrast Anthonisen et al. [21] found in 1987 a
55% success rate with placebo and a 68% response rate
with antibiotic treatment for 10 days. Daniels et al. [15]
observed in 2010 a clinical success in the first study using
a standardized treatment including systemic corticoste-
roids in 61% of patients from the doxycycline group and
53% from the placebo group. In all these studies back-
ground standard of care has not been optimized and it is
assumed that this is the reason for observed differences in
small studies. It is thus assumed that the response rate in
the study population will be in the order of 65%. With a
one-sided type 1 error of 2.5% 479 patients per group have
to be recruited to reject the null-hypothesis of relevant
inferiority of placebo treatment with 90% power and a
non-inferiority margin of 10%. (Sample-size calculation
has been performed with nQuery-Advisor 7.0).
The trial is designed and powered to prove that anti-
biotic therapy is not necessary in addition to standard of
care in patients with moderate AE-COPD with the aim
to reduce unnecessary antibiotic prescriptions and the
ultimate goal to reduce antibiotic resistance. This is the
first study in the field to use a non-inferiority trial design
including a placebo arm. Other trials have used superior-
ity design for antibiotics and yielded inconclusive results.
These trials were all designed with the hypothesis that
antibiotic therapy should be superior to placebo. In this
trial we will investigate whether use of placebo is not
inferior to antibiotic treatment and have chosen a tightnon-inferiority margin to justify that antibiotic treatment
should be withheld in this patient population in the
future. This is clinically relevant for the target popula-
tion as adverse effects and antibiotic resistance could be
decreased if antibiotic treatment will be shown not be
necessary in this trial.
The sample size of this trial is assumed to be sufficient
to determine changes in relapse rates, time to relapse,
clinical cure rates at EOT and TOC and to assess long-
term consequences of sparing anti-biotic treatment.
This is a randomized and double-blind clinical trial
with placebo matching tablets for active treatment.
Block-randomization will be used. Randomization will be
stratified for centre. All randomized patients that have re-
ceived study medication at least once will be included into
the primary intention-to-treat (ITT)-analysis. This is a
non-inferiority trial and usually a per-protocol analysis
would be used as primary analysis. However, the impact of
potential missing values could be anti-conservative in the
per-protocol analysis when demonstrating non-inferiority
to placebo as well (pts with no improvement to placebo
drop) and the ITT population is used here with a strategy
that should maximize differences between treatment
groups in case of uncertainty about outcome, because
irrelevance of differences between treatment strategies
is the objective to be demonstrated. In this complex
situation missing values will be counted as failure in
the placebo-group and as a success for patients in the
antibiotics group. It is obvious that all attempts have to
be undertaken to follow all patients to the end of the
study.
In conclusion we believe that ABACOPD will be the
first sufficiently powered double-blind placebo-controlled
study in the field to systematically assess the question
whether antibiotics, known to increase antibiotic resist-
ance, are really needed in a well-defined patient cohort
receiving state-of-the art treatment in all other aspects.
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